Daniel S Treitler

Daniel S. Treitler is a notable inventor based in Cranford, NJ (US), recognized for his significant contributions to the field of pharmaceuticals. He holds three patents that showcase his expertise in developing innovative processes for synthesizing complex compounds. His work is particularly relevant in the context of treating auto-immune and auto-inflammatory diseases.

Latest Patents

Treitler's latest patents include a process for the preparation of a cyclic dinucleotide, which is useful as a STING agonist. This invention involves the use of specific compounds to enhance the efficacy of the cyclic dinucleotide. Another notable patent is for the preparation of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-D3)pyridazine-3-carboxamide. This compound is currently undergoing clinical trials for the treatment of conditions such as psoriasis.

Career Highlights

Treitler is associated with Bristol-Myers Squibb Company, a leading global biopharmaceutical company. His role at the company allows him to contribute to groundbreaking research and development in the pharmaceutical industry. His innovative approaches have the potential to lead to significant advancements in medical treatments.

Collaborations

Throughout his career, Treitler has collaborated with talented professionals, including Bahar Inankur and Sergei Kolotuchin. These collaborations have fostered an environment of innovation and creativity, further enhancing the impact of their collective work.

Conclusion

Daniel S. Treitler's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in the treatment of various diseases.

This text is generated by artificial intelligence and may not be accurate.